Sidoti downgraded Lemaitre Vascular (NASDAQ:LMAT) from Buy to Neutral in a statement released earlier today.
- Updated: September 22, 2016
Just yesterday Lemaitre Vascular (NASDAQ:LMAT) traded -5.18% lower at $21.62. LMAT’s 50-day average is $18.73 and its two hundred day average is $15.92. With the last stock price close up 28.74% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trade Volume was up over the average, with 190,987 shares of LMAT changing hands over the typical 135,672
Sidoti has downgraded Lemaitre Vascular (NASDAQ:LMAT) from Buy to Neutral in a statement released on 09/22/2016.
Previously on 5/3/2016, Canaccord Genuity reported about Lemaitre Vascular (NASDAQ:LMAT) bumped up the target price from $6.00 to $18.00. At the time, this indicated a possible upside of 0.10%.
Recent Performance Chart
With a total market value of $0, Lemaitre Vascular has PE ratio of 41.16 with a 52 week low of $11.80 and a 52 week high of $22.50 .
In addition to Sidoti reporting its stock price target, a total of 7 brokers have issued a research note on the company. The average stock price target is $17.29 with 5 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 brokerages rating the company a underperform, and lastly zero brokerages rating the company a sell.
General Company Details For Lemaitre Vascular (NASDAQ:LMAT)
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company's product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.